CurrentUnitedHealthcarePolicy CS021.P

Collagen Crosslinks and Biochemical Markers of Bone Turnover

Defines UnitedHealthcare's clinical policy for use and coverage considerations of collagen crosslink and other biochemical bone turnover marker testing (serum/urine) for assessment and management of bone disease; does not apply in several listed states where separate policies/guidelines govern.

Policy Summary

PayerUnitedHealthcare

PolicyCollagen Crosslinks and Biochemical Markers of Bone Turnover

Policy CodePolicy CS021.P

Change TypeNo material change

Effective DateFeb 1, 2025

Next Review Date

Key ActionWhen ordering bone turnover marker testing, prefer standardized serum assays (PINP and ßCTX-I) with early-morning fasting samples and document clinical rationale and specimen handling to support interpretation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

82523example listed procedure code

Multiple (2021-2023)clinical evidence citations

Severalstates with separate policy

10pages

35 RCTssystematic review trials

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Rationale

Described clinical indications and evidence

Clinical uses and evidence summaries included in policy:

Uses described: Assessment of fracture risk, prediction of bone loss, monitoring response to antiresorptive or anabolic therapy, and assisting in individualized osteoporosis management (including perioperative monitoring).

Policy notes controversy and variability in interpretation; often used in research settings; specimen sources include serum and urine with assay variability between laboratories.

Observed marker kinetics and clinical correlations: BTMs such as P1NP and CTX change predictably with therapy (e.g., P1NP increases with teriparatide; CTX decreases with denosumab) and peak during fracture healing (around 6 weeks); elevated 6-week CTX and P1NP associated with radiographic healing at 12 weeks in RCT data.

Findings drawn from multicenter observational studies and RCTs; limitations include small samples, unfasted draws, and short follow-up.

Discriminant cut-offs and predictive findings: In a prospective cohort, P1NP < 30 μg/L and CTX < 0.25 μg/L were the best discriminators of antiresorptive drug (ARD) use and predicted BMD gains after 2 years; P1NP predicted fractures among patients on ARD in that study.

Single-cohort findings require validation; sample sizes modest (e.g., 228 patients in the cited study).

Perioperative monitoring evidence: A small RCT in postmenopausal women undergoing TKA suggested BTM-guided osteoporosis therapy prolonged treatment and was associated with higher BMD and improved early functional outcomes compared with fixed-duration therapy, though follow-up was short and sample size small.

Clinical impact on long-term outcomes remains uncertain due to limited size and follow-up.

Coverage rationale and guideline-consistent criteria

Summarized guidance and evidence regarding use of BTMs:

Guideline monitoring recommendations: Consider measuring reference BTMs to monitor therapy: use a resorption marker (e.g., serum CTX/ßCTX-I) for antiresorptive therapy and a formation marker (e.g., serum PINP) for anabolic therapy; measure at approximately 3–6 months after treatment initiation to identify poor response or nonadherence.

Recommendations referenced from AACE/ACE, Endocrine Society, and older guidelines for men; evidence level and variability noted in source guidelines.

Test selection and pre-analytical handling: Prefer standardized serum assays for PINP and ßCTX-I (IOF/IFCC and ES/working groups) and obtain early-morning fasting samples to reduce diurnal and feeding-related variability.

Guideline panels recommend these specific markers and standardized sampling to minimize pre-analytical variability.

Evidence on prediction and diagnosis: Evidence is mixed: some meta-analyses and cohort studies report associations between higher BTMs and fracture risk or treatment response, but large prospective studies and systematic assessments conclude BTMs do not reliably predict fracture independent of BMD and cannot be used to diagnose osteoporosis; BTMs are not included as risk factors in FRAX.

This Medical Policy does not apply to member populations in the states listed in the policy Application section. Refer to the state-specific policy or guideline where indicated for Idaho, Kansas, Kentucky, Louisiana, New Jersey, New Mexico, Ohio, Pennsylvania, and Tennessee; Indiana and North Carolina have no separate policy listed. Providers should follow the applicable state policy or guideline for coverage determinations in those jurisdictions.

The policy recognizes that bone turnover markers (BTMs) are not included as risk factors in FRAX because evidence that BTMs predict fracture risk independent of bone mineral density (BMD) is inconclusive. BTMs therefore cannot be used as inputs to FRAX or as standalone tests to diagnose osteoporosis; guideline and systematic review findings summarized in the policy conclude the evidence is insufficient to support routine diagnostic use of BTMs for fracture risk prediction or osteoporosis diagnosis.

The policy notes that use of biochemical markers in clinical practice is controversial. Interpretation of BTMs is complex because bone metabolism is intricate and values vary with physiologic and analytic factors. In addition, lack of assay standardization and pre-analytical variability (for example, timing and fasting status) have produced unacceptable inter-laboratory variation, which complicates clinical decision-making based on individual test results.

After review of available studies, the policy indicates that evidence is insufficient to determine that BTMs are medically necessary for diagnosing osteoporosis or for monitoring treatment response in a way that demonstrably changes clinical outcomes. Systematic reviews and technology assessments cited in the policy found mixed results, potential bias in studies, and limited data linking BTM measurements to meaningful outcomes; FDA information likewise does not support BTM use for diagnosis or drug selection.

Coding and Test Identifiers

Commercial Policy - example CPTCPT

82523

Collagen cross links, any method

P1NP and CTX discrimination cut-offs

P1NP discrimination thresholdP1NP < 30 μg/L associated with discrimination of ARD use and prediction of BMD gains

CTX discrimination thresholdCTX < 0.25 μg/L associated with discrimination of ARD use and prediction of BMD gains

Source study populationProspective cohort (Borgen et al. 228 patients, mean follow-up 4.6 years) used to derive thresholds

Provider Actions, Billing & Operational Notes

Prior Authorization

Prior authorization is not specified for biochemical bone turnover marker tests in this segment of the policy. Note that FDA approval or clearance alone does not constitute a basis for coverage decisions; benefit plan terms, federal/state requirements, and applicable laws govern coverage determination.

Prior authorization: None specified in this section; verify member's benefit plan for any PA requirements.
FDA/regulatory note: FDA approval alone is not a basis for coverage; some tests may be CLIA-waived/moderate/high complexity or have 510(k) clearance — check manufacturer and laboratory regulatory status if relevant.
Coverage listing caveat: Inclusion of CPT 82523 (Collagen cross links, any method) in the policy is for reference and does not imply covered or non-covered status; plan benefits govern reimbursement.

Documentation Required

Specimen and Interpretation Considerations

Specimen collection and interpretation require attention to preanalytical factors and assay variability. BTMs may be measured in serum or urine; many assays require early-morning, fasting samples to reduce diurnal variation. Inter-laboratory variability and lack of standardization can affect comparability of results; clinicians should interpret values in the context of the specific assay used and local laboratory reference ranges.

Background and Evidence Summary

Bone turnover markers (BTMs) are biochemical analytes measurable in serum or urine that reflect either bone formation or bone resorption. Formation markers include osteocalcin and bone alkaline phosphatase and markers such as procollagen type I N‑terminal propeptide (PINP); resorption markers include pyridinoline, telopeptides (e.g., CTX/ßCTX‑I), and urinary N‑telopeptide of type I collagen (NTx). These tests are performed by methods such as high performance liquid chromatography or immunoassay and are intended to provide information on the rate of bone remodeling, potential fracture risk, and response to osteoporosis therapies, though clinical application is limited by interpretation and standardization issues.

Definitions and Marker Reference Standards

Bone turnover markers (BTMs)

Formation marker examplesP1NP (procollagen type I N‑terminal propeptide), osteocalcin, bone alkaline phosphatase

Resorption marker examplesCTX (C‑terminal telopeptide/ßCTX‑I), NTx, pyridinoline, urinary cross‑linked N‑telopeptide

Specimen sourcesSerum is preferred for PINP and ßCTX‑I using standardized assays; some markers also measurable in urine (e.g., NTx, pyridinoline)

Preanalytical considerationsEarly‑morning fasting samples and standardized handling recommended to reduce diurnal and feeding variability

PINP — Procollagen type I N‑terminal propeptide

DefinitionProcollagen type I N‑terminal propeptide (PINP) is a serum marker of bone formation